Coeliac Disease: A Common, Under-Diagnosed Autoimmune Condition Where Iron That Will Not Stay Up Is Often the First Clue, and the Only Rule That Matters Before Testing Is Keep Eating Gluten
Summary
Coeliac disease is a lifelong autoimmune reaction to gluten that affects roughly 1 in 100 people, yet only about a quarter are diagnosed, because it so often shows up not as obvious gut trouble but as iron deficiency that keeps coming back or will not respond to supplements, unexplained fatigue, mouth ulcers, or a blistering rash; the first-line screen is a simple blood test (tTG-IgA, requested with a total IgA), a positive result routes to a duodenal biopsy for confirmation in adults, and the single load-bearing rule is that the person must still be eating gluten when tested because going glu
Why Strong
Strong Evidence because the load-bearing claims rest on the strongest available grounds: population prevalence around 1% with a large undiagnosed fraction (consistent population data), tTG-IgA as the guideline first-line screen with meta-analysed accuracy, biopsy confirmation as the adult standard, and a uniform guideline consensus on the gluten-before-testing rule. These are guideline- and meta-analysis-backed, not suggestive.
NOT Foundational because the entry carries clinical judgement and a live surrounding controversy (the gluten-sensitivity market), not a single undisputed axiom.
NOT Moderate for the headline, because the diagnostic spine, common and missed, tTG-IgA-with-total-IgA screen, biopsy confirmation, keep eating gluten, is settled. Only the adult no-biopsy route sits lower, and the entry marks it.
The per-component split (read this, not just the headline):
• tTG-IgA as first-line screen; keep total IgA: Strong (guidelines plus accuracy meta-analysis).
• Gluten-before-testing rail: Strong (uniform consensus, mechanistically necessary).
• Iron-refractory anaemia as a coeliac clue: Strong (established association, clear mechanism).
• Adult no-biopsy (serology-only) diagnosis: Strong-to-Moderate, still consolidating in adults.
• Non-coeliac gluten sensitivity as a real entity: Moderate-to-Emerging, a diagnosis of exclusion, not this entry's subject.
Practical takeaway
The framing to hold: when the pattern fits, name the pattern and route to the test, keep eating gluten until tested, and let the clinician own the diagnosis and the diet.
Recognise the pattern (especially the atypical adult one).
• Iron deficiency, or low folate or B12, that keeps recurring or does not respond to supplements. This is the highest-value clue and the one most often missed.
• Gut symptoms, bloating, diarrhoea, constipation, or abdominal pain, particularly after wheat-based meals. Present in many but not all.
• Persistent fatigue that sleep and recovery do not resolve.
• Recurrent mouth ulcers; an itchy, blistering rash on the elbows, knees, or scalp (dermatitis herpetiformis, near-specific to coeliac disease); unexplained weight loss; or unexplained low bone density in an otherwise low-risk adult.
• A first-degree relative with coeliac disease raises the prior (family risk is roughly 1 in 10).
Route to the screen.
• The first step is a tTG-IgA blood test via the GP, requested together with a total IgA. This is cheap, standard, and the thing that separates coeliac disease from the many other causes of tiredness or low iron.
• A positive result routes to a referral for duodenal biopsy, the adult confirmation standard.
• HLA-DQ2.5/DQ8 typing is a rule-out adjunct for at-risk groups (its strength is exclusion, not confirmation), not a first-line diagnostic test.
The one hard rule: keep eating gluten until testing is complete.
• Aim for gluten in more than one meal a day (roughly two slices of bread's worth) for at least six weeks before testing. Cutting gluten first is the single most common way a diagnosis is lost.
• If someone has already gone gluten-free and coeliac disease is suspected, they should not simply be told to restart on their own; a clinician-supervised gluten challenge is the correct route, and HLA typing can help decide whether it is worth doing.
Let the clinician own diagnosis and treatment.
• Confirmed coeliac disease is treated with a strict, lifelong gluten-free diet, prescribed and supported by a clinician and usually a dietitian, with follow-up serology and nutrient checks. That is a clinical prescription, not a self-started experiment, and it happens only after biopsy confirmation.
Screen first, always. If alarm features are present (see below), the pattern-and-screen route does not apply; that is urgent clinical care, not a differential.
Evidence detail
Why This Entry Exists
Coeliac disease is one of the most common autoimmune conditions there is and one of the most missed. The classic picture taught in medical school, a child with diarrhoea and failure to thrive, describes a minority of cases. In adults it far more often presents obliquely: an iron deficiency that never quite resolves, tiredness that rest does not fix, low bone density found by accident, recurrent mouth ulcers, or an itchy rash. Because none of these points obviously at the gut, the average diagnostic delay runs into years, during which malabsorption quietly does damage that a strict gluten-free diet, the one effective treatment, would have prevented.
This entry exists to hold two things at once. First, coeliac disease is genuinely common, genuinely under-diagnosed, and genuinely worth ruling out when the pattern fits, especially the iron-that-will-not-stay-up pattern. Second, the app's job ends precisely at routing to the test. Coeliac disease is diagnosed by serology plus biopsy and owned by a clinician; the treatment is a lifelong prescription-grade dietary change made only after confirmation. The one hard safety rule that sits above everything else is the sequencing rail: never remove gluten before testing. A person who goes gluten-free on suspicion, or on a well-meaning nudge, sabotages their own chance of a diagnosis.
What bad advice this protects against, in all directions:
• "Try cutting out gluten and see if you feel better" as a first move in someone who has not been tested. This is the single most damaging piece of common-sense advice in this area: it can normalise the antibodies and partially heal the biopsy within weeks, so a real coeliac diagnosis is then missed, and the person carries an untreated autoimmune condition behind a diet that only masks it.
• "Your iron is low, just take more iron" when the iron keeps falling or will not climb. Refractory or unexplained iron deficiency is a recognised presentation of coeliac disease, because the damaged upper small intestine is exactly where iron is absorbed. Repeated topping-up without asking why is how the delay happens.
• "You carry the coeliac gene, so you have it" or "so you should avoid gluten." The HLA-DQ2.5 marker is necessary but nowhere near sufficient; around 30% of people carry it and the large majority never develop the disease. Genotype is a prior, not a diagnosis, and never a reason to pre-emptively remove gluten (hla_dqa1_coeliac).
• "It is probably just IBS" without the coeliac screen. The symptom overlap is real, which is why guidelines recommend serological screening for coeliac disease before settling on IBS (ibs_diagnostic_lifestyle).
• "Coeliac is mild, it is just a food intolerance." Untreated, the long tail is not trivial: osteoporosis, neuropathy, subfertility, and a raised risk of small-bowel lymphoma. The severity is moderate and fully treatable once diagnosed, which is exactly why finding it matters.
This entry owns the coeliac recognition pattern, the screen-and-route pathway, and the gluten-before-testing rail. It defers the genetic-risk interpretation to hla_dqa1_coeliac, the broader tiredness workup to fatigue_cross_pillar_diagnostic, the iron-repletion detail to iron_supplementation_repletion_and_overload, and the IBS overlap to ibs_diagnostic_lifestyle.
Evidence
Prevalence and the diagnostic gap (Strong Evidence).
1. Coeliac disease affects roughly 1% of the population, and most cases are undiagnosed. Population screening and review data put prevalence at around 1% in Europe and the UK, with only a minority formally diagnosed. UK figures suggest roughly a quarter of those affected are diagnosed, meaning the majority remain unrecognised at any given time, the so-called "coeliac iceberg." The undiagnosed fraction is driven by the non-specific and extra-intestinal nature of adult presentation. (Lundin & Wijmenga, Nat Rev Gastroenterol Hepatol 2015, ~1-2% global prevalence; UK population and case-finding data. Strong Evidence, consistent across population studies. Academic and public-health sources, no commercial interest.)
Iron deficiency as a presenting sign (Strong Evidence).
2. Iron-deficiency anaemia is a common extra-intestinal presentation, and refractory iron deficiency is a recognised coeliac clue. Between roughly 3% and 6% of people investigated for iron-deficiency anaemia are found on biopsy to have coeliac disease, and in some presentation series anaemia is the single most common mode of presentation. The mechanistic reason is direct: the proximal small intestine is both the predominant site of coeliac inflammation and the main site of iron absorption, so iron deficiency that is unexplained by intake or loss, or that does not respond to repletion, legitimately raises coeliac suspicion. (Hematologic manifestations reviews; case-finding studies in iron-deficiency anaemia cohorts. Strong Evidence for the association. Independent clinical literature.)
The screen: tTG-IgA plus total IgA (Strong Evidence).
3. IgA anti-tissue-transglutaminase (tTG-IgA) is the first-line serological screen, requested with a total IgA. Guidelines across paediatric and adult gastroenterology recommend tTG-IgA as the initial test, with pooled adult sensitivity around 90% and specificity around 87%. It is requested alongside a total IgA because selective IgA deficiency, present in roughly 1 in 500 people and over-represented in coeliac disease, causes a falsely normal tTG-IgA; in that case an IgG-based test (tTG-IgG or deamidated gliadin peptide IgG) is used instead. (Husby et al., ESPGHAN 2020 guidelines; serology accuracy meta-analyses, Aliment Pharmacol Ther 2022. Strong Evidence, professional-society guidance plus meta-analysis. Professional societies and academic groups.)
Confirmation and the no-biopsy caveat (Strong-to-Moderate).
4. Duodenal biopsy remains the adult confirmation standard, with a serology-only route emerging at very high antibody levels. A positive tTG-IgA in an adult routes to a referral for duodenal biopsy, still the gold standard for confirmation. A no-biopsy approach, diagnosing on very high tTG-IgA (at least ten times the upper limit of normal) with supporting tests, is validated and increasingly used in children and studied in adults, but the biopsy pathway remains standard for most adults. (No-biopsy meta-analysis, Gastroenterology 2023, pooled biopsy-proven prevalence ~62% in that population; ESPGHAN 2020. Strong-to-Moderate, the adult no-biopsy route is still consolidating. Academic and society sources.)
The gluten-before-testing rail (Strong Evidence, consensus).
5. Testing is only valid while the person is eating gluten. Both serology and biopsy depend on an active immune response to gluten. Removing gluten normalises tTG-IgA within weeks and allows the intestinal lining to heal, so a person already on a gluten-free diet cannot be reliably tested and would need a clinician-supervised gluten challenge (typically eating gluten daily for around six weeks) before valid testing. Guidance is uniform that the diet must not be changed before testing. (ESPGHAN 2020; BSG and coeliac-society guidance; consistent guideline consensus. Strong Evidence. Professional-society consensus, the safety gate.)
Mechanism
Why gluten triggers an immune attack in susceptible people. Wheat, barley, and rye contain gluten proteins rich in proline and glutamine that resist full digestion, so large fragments survive into the small intestine. An enzyme there, tissue transglutaminase (tTG), modifies these fragments (deamidation), and in people carrying the HLA-DQ2.5 or DQ8 immune type these modified fragments fit the antigen-presenting groove with high affinity. That presentation drives a sustained T-cell response against the intestinal lining. The antibodies this generates (anti-tTG) are what the blood test measures; the resulting damage is what the biopsy sees. Full genetic detail is owned by hla_dqa1_coeliac.
Why the villi and their loss explain the whole symptom pattern. The immune response flattens the intestinal villi (villous atrophy), shrinking the absorptive surface of the proximal small intestine. Because that region absorbs iron, folate, calcium, and fat-soluble vitamins, the downstream picture is malabsorptive: iron deficiency that resists oral repletion, folate or B12 shortfalls, low bone density from poor calcium and vitamin D absorption, and general fatigue. This is why "iron that will not stay up" is such a load-bearing clue: it is not an intake problem or a bleeding problem, it is a damaged-surface problem.
Why removing gluten before testing destroys the test. The whole diagnostic chain depends on an active reaction. Take gluten away and the antibodies fall and the villi begin to regrow, so within weeks both the serology and the biopsy can look normal even in someone who genuinely has the disease. There is no mechanism by which pre-emptive gluten avoidance prevents coeliac disease; it only hides it. This is the mechanistic basis of the sequencing rail.
Risks And Contraindications
• The gluten-before-testing rail overrides everything. Never advise, imply, or nudge a gluten-free trial in anyone who has not been tested and who might have coeliac disease. Doing so can make the diagnosis unobtainable and leave real autoimmune disease untreated behind a masking diet. This is the defining coeliac safety hazard.
• Treatment is prescription-grade and clinician-owned. The lifelong gluten-free diet is started only after a confirmed diagnosis, directed by a clinician. The app routes to the test; it never prescribes the diet, estimates coeliac status, or fills the gap between suspicion and diagnosis.
• Do not diagnose from genotype. Around 30% of people carry HLA-DQ2.5 and the large majority never develop coeliac disease. A carrier result is awareness, not a diagnosis, and never a reason to remove gluten pre-emptively (hla_dqa1_coeliac).
• The IgA-deficiency false negative. A normal tTG-IgA in someone with selective IgA deficiency is falsely reassuring; a total IgA must be requested alongside it, and an IgG-based test used if IgA is low.
• Refractory iron deficiency needs its own workup, not just a coeliac screen. Unexplained iron deficiency in men or postmenopausal women independently warrants investigation for gastrointestinal blood loss. A coeliac screen must not displace that; the two can and should run in parallel.
• Red-flag features route to urgent care. Significant unintentional weight loss, gastrointestinal bleeding or black stools, and severe or acute symptoms are not material for a screen; they defer to the red-flag interrupt and urgent clinical assessment.
Controversy
Nature: the science of coeliac diagnosis is settled; the controversy sits around it, in the popular framing of gluten. A large "gluten-free" wellness market, and a genuine but poorly-defined condition (non-coeliac gluten sensitivity), sit alongside a real, testable autoimmune disease and pull people toward the one action, self-directed gluten avoidance, that most undermines proper diagnosis.
Position A, the grounded clinical take. Coeliac disease is a well-characterised autoimmune condition with a validated screen (tTG-IgA with total IgA) and a confirmatory biopsy. It is common and under-diagnosed, iron-refractory anaemia and fatigue are legitimate presentations, and the diagnostic pathway must be completed while eating gluten. Where this goes wrong if overstated: turning every bloated-after-bread person into a suspected coeliac, manufacturing anxiety rather than routing the genuine pattern.
Position B, the wellness-market take. "Gluten is inflammatory, most people feel better without it." Best evidence for the kernel: non-coeliac gluten (or wheat) sensitivity appears to be real for some people, who report symptom relief off gluten without coeliac serology or biopsy findings. Where it goes badly wrong: it drives pre-emptive, untested gluten avoidance, which is exactly what makes coeliac disease undiagnosable, and it sells a lot of products. Non-coeliac gluten sensitivity is a diagnosis of exclusion made after coeliac disease has been ruled out on a gluten-containing diet, not a reason to skip testing.
The funding/bias dimension, cui bono. The commercial pressure runs toward selling gluten-free products and pushing self-directed avoidance, which is the framing that harms diagnosis. The clean signals are the un-sponsored ones: a cheap first-line blood test, professional-society guidelines with no product to sell, and the unglamorous rule to keep eating ordinary bread until you have been tested.
Realised Position: Coeliac disease is common, commonly missed, and worth ruling out when the pattern fits, above all when iron will not stay up. Name the pattern, route to the tTG-IgA-with-total-IgA screen, and hold the line that the person must keep eating gluten until testing is done. Diagnosis is serology-plus-biopsy and belongs to a clinician; the gluten-free diet is a post-diagnosis prescription, never a self-started trial. Reject the "just try cutting gluten" reflex outright, because it is precisely the move that hides the disease.
Cross-Pillar Connections
Genuinely cross-pillar: a diet-triggered autoimmune condition presenting through fatigue, iron status, and bone health.
• Genetic risk (hla_dqa1_coeliac): owns the HLA-DQ2.5/DQ8 interpretation and the carrier-is-not-a-diagnosis framing; this entry routes there for genotype and holds the clinical recognition pattern.
• Fatigue (fatigue_cross_pillar_diagnostic): owns the systematic tiredness workup in which coeliac disease is one item; this entry holds the coeliac-specific screen and rail.
• Iron (iron_supplementation_repletion_and_overload): owns iron repletion detail; this entry holds the "refractory or unexplained iron deficiency raises coeliac suspicion" link and the do-not-just-top-up caution.
• IBS (ibs_diagnostic_lifestyle): owns functional-gut management; this entry holds the rule that coeliac disease is screened for before settling on IBS.
• Immune (immune_function_cross_pillar_optimisation): coeliac disease clusters with other autoimmune conditions (type 1 diabetes, autoimmune thyroid disease); relevant when several autoimmune markers co-occur.
What would change our mind
• We would revise the screening framing if a validated, gluten-independent diagnostic (one that works regardless of current gluten intake) became standard, removing the sequencing rail. No such test is standard today.
• We would broaden the adult no-biopsy route if adult data consolidated to the point that guidelines dropped routine biopsy for high-titre tTG-IgA, as has largely happened in children.
• We would downgrade the iron-refractory clue if large cohorts showed that unexplained or refractory iron deficiency did not enrich for coeliac disease above base rate. Current data show the opposite.
• What would NOT move us: the gluten-before-testing rail (guideline-uniform and mechanistically necessary), the requirement to request total IgA alongside tTG-IgA, or the principle that diagnosis and the gluten-free diet are clinician-owned.
Industry bias note
Cui bono points mostly one way here, toward self-directed gluten avoidance.
• Toward under-diagnosis via the wellness market. The gluten-free food and supplement market benefits from the message that anyone might feel better off gluten. That message drives untested avoidance, the exact behaviour that makes coeliac disease undiagnosable. It is a commercial engine pointed away from proper diagnosis.
• The clean, un-sponsored signals. The first-line screen is a cheap blood test with no product attached, the confirmation is a clinical procedure, and the guidelines come from professional societies with no gluten-free brand to sell. The load-bearing safety rule, keep eating ordinary gluten until tested, sells nothing and is exactly the one the market's framing works against.
• The net rule: trust the cheap screen, the biopsy, and the guideline consensus; apply the most scepticism to any "just cut gluten and see" advice, which is both commercially convenient and diagnostically destructive.
Sources (7)
- Lundin KEA, Wijmenga C. (2015). "Coeliac disease and autoimmune disease, genetic overlap and screening." Nature Reviews Gastroenterology & Hepatology;12(9):507-515. (Independent/academic.) Prevalence ~1-2% globally; ~30% of Europeans carry HLA-DQ2.5 but only ~3% of carriers develop disease; environmental triggers reviewed.↗
- UK population and case-finding data on the diagnostic gap. (Public-health and academic sources.) Prevalence ~1% with roughly a quarter diagnosed, the "coeliac iceberg", driven by non-specific and extra-intestinal presentation.↗
- Hematologic manifestations of coeliac disease; iron-deficiency-anaemia case-finding cohorts. (Independent clinical literature.) 3-6% of iron-deficiency-anaemia investigations yield biopsy-confirmed coeliac disease; the proximal small intestine is both the inflammation site and the iron-absorption site, explaining refractory iron deficiency.↗
- Husby S, et al. (2020). "ESPGHAN Guidelines for Diagnosing Coeliac Disease 2020." J Pediatr Gastroenterol Nutr;70(1):141-156. (Professional society.) tTG-IgA first-line with total IgA; HLA typing for at-risk groups; must be on a gluten-containing diet for valid testing.↗
- Serological-accuracy meta-analysis. Aliment Pharmacol Ther 2022. (Academic.) Adult tTG-IgA pooled sensitivity ~90.7%, specificity ~87.4%.↗
- No-biopsy-approach systematic review and meta-analysis. Gastroenterology 2023 (searched 1998 to Oct 2023; 18 studies, 12,103 participants; pooled biopsy-proven prevalence ~62% in the tested population). (Academic.) Very high tTG-IgA (>=10x ULN) supports a serology-based diagnosis; biopsy remains standard for most adults.↗
- Funding notation: the anchors are professional-society guidelines and independent academic syntheses with no product to sell. The most commercially-motivated message in this space, self-directed gluten avoidance, is the one the entry marks as diagnostically destructive and refuses to endorse.*↗